Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats.

Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone PJ.

Invest Radiol. 2002 Jun;37(6):321-7.

PMID:
12021588
2.

Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates.

Fournier J, Steinberg R, Gauthier T, Keane PE, Guzzi U, Coudé FX, Bougault I, Maffrand JP, Soubrié P, Le Fur G.

Neuroscience. 1993 Aug;55(3):629-41.

PMID:
8413926
3.

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.

Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

PMID:
18462720
4.

In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.

Petty MA, Neumann-Haefelin C, Kalisch J, Sarhan S, Wettstein JG, Juretschke HP.

Eur J Pharmacol. 2003 Aug 1;474(1):53-62.

PMID:
12909195
5.

Rodent stroke induced by photochemical occlusion of proximal middle cerebral artery: evolution monitored with MR imaging and histopathology.

Chen F, Suzuki Y, Nagai N, Jin L, Yu J, Wang H, Marchal G, Ni Y.

Eur J Radiol. 2007 Jul;63(1):68-75. Epub 2007 Mar 6.

PMID:
17337149
6.

Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.

van Vliet SA, Blezer EL, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH.

Brain Res. 2008 Jan 16;1189:219-28. Epub 2007 Nov 1. Erratum in: Brain Res. 2008 Apr 14;1204:123. van Vlieta, S A M [corrected to van Vliet, S A M].

PMID:
18076869
7.

Src family kinase-inhibitor PP2 reduces focal ischemic brain injury.

Lennmyr F, Ericsson A, Gerwins P, Akterin S, Ahlström H, Terént A.

Acta Neurol Scand. 2004 Sep;110(3):175-9.

PMID:
15285775
8.

What we have learned from the Xaliproden Sanofi-aventis trials.

Douillet P, Orgogozo JM.

J Nutr Health Aging. 2009 Apr;13(4):365-6. No abstract available.

PMID:
19300882
9.

Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia.

Martínez-Orgado J, Fernández-Frutos B, González R, Romero E, Urigüen L, Romero J, Viveros MP.

Brain Res Mol Brain Res. 2003 Jun 10;114(2):132-9.

PMID:
12829323
10.

Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type.

Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, Ahmad A, Shrivastav P, Islam F.

Brain Res. 2009 Jul 24;1281:117-27. doi: 10.1016/j.brainres.2009.04.010. Epub 2009 Apr 15.

PMID:
19374888
11.

The effects of dantrolene on hypoxic-ischemic injury in the neonatal rat brain.

Gwak M, Park P, Kim K, Lim K, Jeong S, Baek C, Lee J.

Anesth Analg. 2008 Jan;106(1):227-33, table of contents. doi: 10.1213/01.ane.0000287663.81050.38.

PMID:
18165582
12.

Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage.

Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M, Balduini W, Paoletti R, Tremoli E.

Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):322-7.

13.

The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques.

Haga KK, Gregory LJ, Hicks CA, Ward MA, Beech JS, Bath PW, Williams SC, O'Neill MJ.

Brain Res. 2003 Dec 12;993(1-2):42-53.

PMID:
14642829
14.

Effects of xaliproden, a 5-HT₁A agonist, on mechanical allodynia caused by chemotherapeutic agents in mice.

Andoh T, Sakamoto A, Kuraishi Y.

Eur J Pharmacol. 2013 Dec 5;721(1-3):231-6. doi: 10.1016/j.ejphar.2013.09.030. Epub 2013 Sep 23.

PMID:
24070812
15.
17.

SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.

Porzner M, Müller T, Seufferlein T.

Expert Opin Investig Drugs. 2009 Nov;18(11):1765-72. doi: 10.1517/13543780903329089. Review.

PMID:
19814656
18.

Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion- and T2-weighted magnetic resonance imaging.

Bhagat YA, Obenaus A, Hamilton MG, Mikler J, Kendall EJ.

Neurotoxicology. 2005 Dec;26(6):1001-13. Epub 2005 Jun 27.

PMID:
15982742
19.

Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study.

Dijkhuizen RM, Singhal AB, Mandeville JB, Wu O, Halpern EF, Finklestein SP, Rosen BR, Lo EH.

J Neurosci. 2003 Jan 15;23(2):510-7.

20.

Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT).

Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A, Islam F.

Eur Neuropsychopharmacol. 2009 Sep;19(9):636-47. doi: 10.1016/j.euroneuro.2009.02.002. Epub 2009 Mar 28.

PMID:
19329286
Items per page

Supplemental Content

Write to the Help Desk